c-Kit-dependent growth of uveal melanoma cells:: A potential therapeutic target?

被引:57
作者
All-Ericsson, C
Girnita, L
Müller-Brunotte, A
Brodin, B
Seregard, S
Östman, A
Larsson, O
机构
[1] Karolinska Hosp, Dept Pathol & Oncol, S-17176 Stockholm, Sweden
[2] St Eriks Eye Hosp, Stockholm, Sweden
[3] Ludwig Inst Canc Res, S-75124 Uppsala, Sweden
关键词
D O I
10.1167/iovs.03-1196
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. This study was conducted to investigate the expression and functional impact of the proto-oncogene c-kit in uveal melanoma. METHODS. Based on immunohistochemical (IHC) study of paraffin-embedded specimens from 134 uveal melanomas and Western blot analysis on eight fresh-frozen samples the expression of c-kit in uveal melanoma was studied. Furthermore, the phosphorylation of c-kit and the impact of the tyrosine kinase inhibitor STI571 was examined in the three uveal melanoma cell lines OCM-1, OCM-3, and 92-1. RESULTS. Eighty-four of 134 paraffin-embedded samples and six of eight fresh-frozen samples expressed c-kit. c-Kit was strongly expressed and tyrosine phosphorylated in cultured uveal melanoma cells compared with cutaneous melanoma cells. Moreover, in contrast to cutaneous melanoma cell lines c-kit maintained a high phosphorylation level in serum-depleted uveal melanoma cells. No activation-related mutations in exon 11 of the KIT gene were found. On the contrary, expression of the stem cell growth factor (c-kit ligand) was detected in all three uveal melanoma cell lines, suggesting the presence of autocrine (paracrine) stimulation pathways. Treatment of uveal melanoma cell lines with STI571, which blocks c-kit autophosphorylation, resulted in cell death. The IC50 of the inhibitory effects on c-kit phosphorylation and cell proliferation was of equal size and less than 2.5 muM. CONCLUSIONS. The results confirm that c-kit is vastly expressed in uveal melanoma, suggest that the c-kit molecular pathway may be important in uveal melanoma growth, and point to its use as a target for therapy with STI571.
引用
收藏
页码:2075 / 2082
页数:8
相关论文
共 43 条
[1]  
All-Ericsson C, 2002, INVEST OPHTH VIS SCI, V43, P1
[2]  
Allander SV, 2001, CANCER RES, V61, P8624
[3]  
ALLERICSSON C, 2002, UVEAL MELANOMA CYTOG
[4]  
BarEli M, 1997, J CELL PHYSIOL, V173, P275, DOI 10.1002/(SICI)1097-4652(199711)173:2<275::AID-JCP35>3.0.CO
[5]  
2-C
[6]  
Bergman L, 2002, INVEST OPHTH VIS SCI, V43, P2579
[7]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[8]   Bcr-Abl inhibition as a modality of CML therapeutics [J].
Buchdunger, E ;
Matter, A ;
Druker, BJ .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2001, 1551 (01) :M11-M18
[9]   Disease and "dis-ease" in patients with uveal melanoma [J].
Damato, B .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2000, 84 (04) :343-344
[10]   ESTABLISHMENT AND CHARACTERIZATION OF AN UVEAL-MELANOMA CELL-LINE [J].
DEWAARDSIEBINGA, I ;
BLOM, DJR ;
GRIFFIOEN, M ;
SCHRIER, PI ;
HOOGENDOORN, E ;
BEVERSTOCK, G ;
DANEN, EHJ ;
JAGER, MJ .
INTERNATIONAL JOURNAL OF CANCER, 1995, 62 (02) :155-161